^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Avastin (bevacizumab)

    i
    Other names: R 435, RG435, R435, rhuMAb-VEGF, RO-4876646, RG 435, RO4876646, R-435, RG-435, RO 4876646
    Company:
    Roche
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    20h
    Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=33, Active, not recruiting, Sir Run Run Shaw Hospital
    New P2 trial
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr)
    1d
    Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=54, Active, not recruiting, CanariaBio Inc. | Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2 | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Apr 2024 --> Oct 2025
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Platinum sensitive
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • OvaRex (oregovomab)
    1d
    Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases (clinicaltrials.gov)
    P3, N=220, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab)
    1d
    An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) (clinicaltrials.gov)
    P3, N=49, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel • Xtandi (enzalutamide) • pemetrexed
    2d
    POCHI: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate (clinicaltrials.gov)
    P2, N=55, Recruiting, Federation Francophone de Cancerologie Digestive | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • capecitabine • oxaliplatin
    4d
    FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer (clinicaltrials.gov)
    P2/3, N=220, Not yet recruiting, Shanghai 10th People's Hospital
    New P2/3 trial
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan
    4d
    IMMUNOLIFE2: Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=162, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • MaaT033 • Navelbine oral (vinorelbine tartrate oral)
    4d
    Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan (clinicaltrials.gov)
    P1, N=694, Recruiting, AbbVie | N=512 --> 694 | Trial primary completion date: Jul 2026 --> Jul 2027
    Enrollment change • Trial primary completion date • Adverse events • First-in-human
    |
    PD-1 (Programmed cell death 1)
    |
    BRAF V600E • BRAF V600 • HER-2 mutation
    |
    Avastin (bevacizumab) • budigalimab (ABBV-181) • telisotuzumab adizutecan (ABBV-400)
    4d
    Toco-CoR: Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, Vejle Hospital | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium
    5d
    Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, University of Wisconsin, Madison | Active, not recruiting --> Recruiting | N=25 --> 50 | Trial completion date: Jul 2026 --> Jul 2028 | Trial primary completion date: Jul 2026 --> Jul 2028
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 positive • RAS wild-type • RAS wild-type + HER-2 positive • HER-2 positive + RAS wild-type
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • Onivyde (nanoliposomal irinotecan)
    5d
    High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis (clinicaltrials.gov)
    P2, N=46, Completed, Sun Yat-sen University | Recruiting --> Completed | N=30 --> 46
    Trial completion • Enrollment change
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Avastin (bevacizumab) • pemetrexed • Ivesa (firmonertinib)
    6d
    A review of the current evidence for maintenance therapy in gastric cancer. (PubMed, Front Pharmacol)
    Among them, capecitabine, S-1, bevacizumab, and avelumab were most frequently evaluated. MT, whether applied as a continuous or switching strategy, may sustain clinical benefits without compromising QoL due to severe AEs. Future studies should investigate the long-term clinical benefits of MT and its impact on resource utilization and health-related QoL.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    Avastin (bevacizumab) • Bavencio (avelumab) • capecitabine